• Raffaella Brugnoni, Lorenzo Maggi, Eleonora Canioni, Isabella Moroni, Chiara Pantaleoni, Stefano D'Arrigo, Daria Riva, Ferdinando Cornelio, Pia Bernasconi, and Renato Mantegazza.
• Laboratory NBS Biotech, Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
• J. Neurol. 2010 Jul 1;257(7):1119-23.

AbstractCongenital myasthenic syndromes are rare genetic disorders compromising neuromuscular transmission. The defects are mainly mutations in the muscle acetylcholine receptor, or associated proteins rapsyn and Dok-7. We analyzed three unrelated Italian patients with typical clinical features of congenital myasthenic syndrome, who all benefitted from cholinesterase inhibitors. We found five mutations: a previously unreported homozygous alphaG378D mutation in the CHRNA1 gene, a previously unreported heterozygous epsilonY8X mutation associated with a known heterozygous epsilonM292del deletion in the CHRNE gene, and the common heterozygous N88K mutation associated with a previously unreported heterozygous IVS1 + 2T > G splice site mutation in the RAPSN gene. All three patients had two mutant alleles; parents or offspring with a single mutated allele were asymptomatic, thus all mutations exerted their effects recessively. The previously unreported mutations are likely to reduce the number of AChRs at the motor endplate, although the alphaG378D mutation might produce a mild fast channel syndrome. The alphaG378D mutation was recessive, but recessive CHRNA1 mutations have rarely been reported previously, so studies on the effect of this mutation at the cellular level would be of interest.

26 keywords...

hide…